Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD

Written by Brittney Marzullo-Sojeva on 4th March 2019. Posted in Client News.

• Previous
• Next